Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR35579798

· D

4c535952-cd1b-5407-b2a0-88d15713d3ff

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.550
  • INTERFERON_GAMMA_RESPONSE+0.490
  • E2F_TARGETS+0.440
  • IL6_JAK_STAT3_SIGNALING+0.430
  • ALLOGRAFT_REJECTION+0.410
  • G2M_CHECKPOINT+0.400
  • INFLAMMATORY_RESPONSE+0.350
  • MITOTIC_SPINDLE+0.300
  • COMPLEMENT+0.260
  • MYC_TARGETS_V2+0.260

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.470
  • ANGIOGENESIS-0.440
  • ESTROGEN_RESPONSE_LATE-0.390
  • MYOGENESIS-0.350
  • ANDROGEN_RESPONSE-0.320
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
  • OXIDATIVE_PHOSPHORYLATION-0.320
  • CHOLESTEROL_HOMEOSTASIS-0.310
  • APICAL_SURFACE-0.300
  • TGF_BETA_SIGNALING-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-B6-A0RT-01A-21R-A084-07
breast-umap@18
D0.869
2SRR8613746
breast-umap@18
D0.840
3SRR8613734
breast-umap@18
D0.840
4MBCproject_0095_T3_RNA
breast-umap@18
E0.829
5MBCProject_5971_T1_RNA
breast-umap@18
D0.829
6TCGA-AR-A1AW-01A-21R-A12P-07
breast-umap@18
D0.818
7SRR1313128
breast-umap@18
D0.815
8SRR8942983
bladder-landscape@3
0.811
9TCGA-GM-A2DH-01A-11R-A180-07
breast-umap@18
C0.810
10AUR-AF95-TTP1-A-1-0-R-A741-41
breast-umap@18
D0.805

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.550Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.490Idelalisib— uncovered
E2F_TARGETS0.440Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.430Inavolisib— uncovered
ALLOGRAFT_REJECTION0.410Idelalisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.350Idelalisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
COMPLEMENT0.260Inavolisib— uncovered
MYC_TARGETS_V20.260Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.190Inavolisib— uncovered
IL2_STAT5_SIGNALING0.130Idelalisib— uncovered
DNA_REPAIR0.080Idelalisib— uncovered
KRAS_SIGNALING_UP0.070Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.060Inavolisib— uncovered
BILE_ACID_METABOLISM0.050Inavolisib— uncovered
UV_RESPONSE_DN0.050Inavolisib— uncovered
NOTCH_SIGNALING0.020Inavolisib— uncovered
SPERMATOGENESIS0.010Inavolisib— uncovered